~~<i id='9438838459'><strike id='9438838459'><tt id='9438838459'><pre id='9438838459'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

explore

author：hotspot 2025-09-30 22:03:57 - browse：98481

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： World's first CRISPR

explore

leisure time

focus

explore

hotspot

AdobeNovoNordisk’sobesitydrugWegovycuttheriskofmajorheartcomplicationsby20%inacloselywatchedtrial,re

WSS

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Does good food count as health care? Study aims to find out

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Wegovy, Zepbound and weight loss drugs that preserve muscle

Wegovy cuts risk of cardiovascular events by 20%, study finds

Astronauts get first look at the spacecraft that will fly them around the moon

knowledge

explore

explore

Medicare details structure of new drug price negotiation program

Why medical students are struggling with mental health

Alkermes shareholders re

Congress must reauthorize a committee to support older Americans

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Malaria cases in Florida and Texas: Here’s what you need to know

Ohioans vote in high

What does generative AI mean for health care? We asked experts

Wegovy, Zepbound and weight loss drugs that preserve muscle

leisure time

Hospitals use virtual reality to design more inclusive rooms for kids

FDA's Woodcock to retire early next year

Anthos stroke drug appears safer than common blood thinner

Zapping the brain for stroke rehab: Pivotal clinical trial begins

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

focus

explore

explore

hotspot